Pfizer to expand clinical trials in Asia, work on development of antibiotics for drug-resistant TB
The pharmaceutical company Pfizer said on Wednesday that it plans to increase the number
of clinical trials it's conducting in
for diseases prevalent in the region," Reuters reports.
"Its clinical research unit in
"The
of clinical trials rise 35 percent since 2001," channelnewsasia.com writes.
Pfizer also "said it will collaborate with closely held MicuRx Pharmaceuticals Inc., based in Union City, California, and China-based Cumencor Pharmaceuticals Inc. to develop antibiotics for drug-resistant TB in China," Bloomberg reports. "